The Transition from Serology to DNA Profiling in Forensic Science

From the 1920s through the 1980s, forensic biology depended on serological marker systems. ABO blood grouping, developed clinically by Karl Landsteiner in 1901, was adopted by forensic laboratories because the antigens are stable in dried stains and can survive for years if conditions are reasonable. Added to ABO were secretor status, the MN system, Rh subtypes, and enzyme polymorphisms such as PGM (phosphoglucomutase) and EAP (erythrocyte acid phosphatase). Combined typing at several systems could, in favourable samples, achieve discriminating power values of 98 to 99 percent, meaning fewer than two in a hundred people shared the same combined type.

The Colin Pitchfork case in England in 1986 exposed the ceiling of serology. Two murders had produced semen stains typed as group A secretor, matching roughly 10 percent of the male population, including an innocent suspect who had confessed under pressure. Alec Jeffreys applied his newly developed RFLP profiling technique and was able to show that the stains from both murders came from the same individual and that the individual was not the confessing suspect. This was the first use of DNA profiling to exonerate someone and then, following a mass screening, to convict the actual perpetrator. The Pitchfork case did not merely add a new tool: it demonstrated that serological individualisation had a fundamental ceiling that DNA transcended.

The structural limitation of serology is that blood group antigens are the product of a small number of genes, each with a limited number of alleles in common circulation. ABO has four common phenotypes. Even combining ten serological marker systems, the number of distinguishable types is finite and small relative to the size of a national population. Any given combined serological type will match thousands or millions of people. DNA, by contrast, uses loci where the number of repeats at each locus varies widely and where the combination of types across loci follows a multiplication rule that drives match probabilities to astronomically low values.

The first DNA profiling method, restriction fragment length polymorphism (RFLP) analysis, required relatively large quantities of intact high-molecular-weight DNA, limiting its application to fresh or well-preserved samples. The introduction of the polymerase chain reaction (PCR) in the late 1980s changed this. PCR amplifies specific short DNA sequences from tiny starting quantities, including highly degraded samples. Combined with STR typing at multiple loci, PCR-based profiling became both sensitive and highly discriminating.

National DNA database systems formalised the advantage. The United Kingdom established the National DNA Database (NDNAD) in 1995, now one of the largest per-capita databases globally. The United States maintains CODIS (Combined DNA Index System), which uses a core set of STR loci standardised to allow inter-laboratory comparison and database searching. India's DNA Technology (Use and Application) Regulation Bill, though not yet enacted as legislation, and the forensic science provisions of the Bharatiya Nagarik Suraksha Sanhita 2023 reflect regulatory preparation for national DNA database infrastructure. The EU's Prum Convention framework enables cross-border DNA database searching between member states. The discriminating power of a profile does not change by country, but the ability to search it against reference populations does depend on database size and standardisation.

Modern multiplex STR kits amplify between 15 and 24 loci in a single reaction. The United States CODIS core expanded from thirteen to twenty loci in 2017. The European standard set (ESS) covers sixteen loci. UK laboratories use the Applied Biosystems GlobalFiler or equivalent kits. Each additional locus multiplies the discriminating power further. The result is that a full profile from a fresh biological stain is, for all practical purposes, a unique biological identifier for any individual not an identical twin.

DNA profiling tells a court whose biological material was present. It does not tell the court what that material was. Identifying the body fluid type is legally significant because the biological context of a stain can determine the charge or the available defences. Semen found on a complainant's clothing is relevant to a sexual assault investigation in a way that blood from a different source is not. Courts in most common-law and civil-law jurisdictions treat the identification of fluid type as a required foundation before the significance of a DNA match can be properly explained to a jury.

Immunological methods are the standard for fluid confirmation. For blood, the Kastle-Meyer colorimetric test is the most widely used presumptive test, but the confirmatory test for blood as a specific species product is the Takayama (haemochromogen) crystal test or, in some laboratories, a lateral-flow immunochromatographic strip using antibodies specific to human haemoglobin. For semen, the prostate-specific antigen (p30) ELISA or lateral-flow strip is the international standard confirmatory test. For saliva, amylase activity assays are used presumptively, with RNA-based methods increasingly used as confirmation in well-resourced laboratories. Vaginal secretions are confirmed by the presence of cornified epithelial cells and, increasingly, by microbiome profiling.

The immunological tests used for fluid identification are separate from the earlier serological typing systems. A p30 ELISA confirms the presence of semen regardless of the blood group of the individual who deposited it. A human haemoglobin lateral-flow strip confirms the stain is human blood regardless of the ABO type. These tests are antigen-specific, not blood-group-specific. They do not provide individualization information but they do provide the biological context without which a DNA profile's significance cannot be fully explained.

• Blood: Kastle-Meyer (presumptive) followed by human haemoglobin lateral-flow strip or Takayama crystal test (confirmatory).
• Semen: acid phosphatase (presumptive) followed by p30/PSA ELISA or lateral-flow strip (confirmatory).
• Saliva: amylase Phadebas test (presumptive) followed by RNA profiling or immunochromatographic strip (confirmatory).
• Species origin: Ouchterlony double diffusion or latex agglutination using species-specific antisera confirms human origin before DNA is extracted.

The precipitin test, first applied forensically by Paul Uhlenhuth in 1901, remains in active use. The principle is simple: if human-specific antisera form a precipitation line against an extract of the stain, the stain contains human protein. If it does not precipitate, the stain is of animal origin or too degraded to produce a result. The Ouchterlony double diffusion method places the antiserum and the stain extract in separate wells in an agarose gel, separated by a few millimetres. As both diffuse toward each other, they meet and form a visible band if the antigen-antibody match is specific.

Precipitin testing matters in cases where animal blood is introduced to obscure or simulate human blood evidence, in hunting-related investigations, in poaching cases, and in situations where the origin of a biological stain found in an unusual context requires clarification before a human-focused investigation is justified. It is also used in cases of alleged animal cruelty or illegal slaughter. The test is inexpensive, requires minimal equipment, and produces a clear visual result. Latex agglutination kits using immobilised antibodies are a faster modern alternative that provides the same species confirmation in minutes.

The cross-link to forensic serology is direct here: precipitin testing is serological in mechanism but functions in the modern workflow as a preliminary species gate rather than an individualisation step. Its role has not been displaced by DNA profiling because DNA typing does not require a species confirmation step in the same way; however, best practice in most national guidelines still requires confirming human origin before expending resources on human STR profiling.

The evidentiary handling of serological versus DNA results differs across legal systems, but the direction of travel is the same. Serological typing results are treated as corroborative at best. They can be admitted as evidence that a stain is consistent with the accused's blood type, but consistency with a blood type shared by 10 to 45 percent of the population has minimal probative value.

In the United States, DNA evidence is governed by Daubert standards for scientific admissibility, and STR profiling is well established as satisfying those standards. ABO serology is admissible but rarely presented as significant because of its limited discriminating power. In the United Kingdom, the Forensic Science Regulator's Codes of Practice set out validation requirements for all forensic methods; both DNA and serological methods must meet these standards, but DNA profiling has been the primary identification tool since the early 1990s. In India, section 45 of the Bharatiya Sakshya Adhiniyam 2023 (which replaced the Indian Evidence Act 1872) governs expert opinion evidence including forensic evidence; DNA evidence is treated as expert evidence and is regularly admitted, while serological results appear in older cases and in those where DNA was unavailable or inconclusive. The EU's approach varies by member state, but the Prum Convention's DNA sharing framework reflects the primacy of DNA as the cross-border identification tool.

The shift in evidential weight from serology to DNA has also affected how historical cases are revisited. Convictions secured primarily on serological evidence have been challenged in several jurisdictions using post-conviction DNA testing. In the United States, the Innocence Project has used post-conviction STR typing of retained evidence samples to exonerate more than 200 individuals, some of whose convictions relied substantially on serological match evidence. The UK Criminal Cases Review Commission has reviewed cases with similar profiles. These exonerations are not evidence that serology was fraudulently presented; they are evidence that its discriminating power was insufficient for the evidentiary weight placed on it.

The current standard workflow in forensic biology treats immunological methods and DNA profiling as sequential stages of a single analytical process, not as competing alternatives. The sequence is designed to preserve sample integrity while extracting maximum information.

Stage one is visual and non-destructive examination: noting the location, size, shape, and colour of a stain and photographing it before any chemical or physical testing. Stage two is presumptive testing using colorimetric or enzymatic reactions that detect haem groups, acid phosphatase, or amylase. These are presumptive, not confirmatory, and positive results do not prove the identity of a fluid. Stage three is confirmatory immunological testing using ELISA, lateral-flow strips, or Ouchterlony methods to establish the fluid type and confirm human origin. Stage four is DNA extraction and quantification. Stage five is STR profiling and interpretation.

Each stage gates the next. Confirmatory fluid identification in stage three is required before the DNA profile from stage five can be contextualised. A DNA profile from an unidentified stain on a garment proves biological contact; the same DNA profile from a stain confirmed as semen proves sexual contact. The immunological stage does not merely precede DNA: it determines the evidential significance of the DNA result. This is why the transition from serology to DNA profiling did not eliminate immunological methods from forensic biology; it reframed them as a required preparatory stage.

For practitioners entering this field, the practical implication is that competence in forensic biology requires proficiency in both domains. Understanding the immunological basis of body-fluid identification, species confirmation, and the historical serological individualisation methods is necessary to understand why the current workflow is structured as it is, how to interpret results from older cases that relied on serology, and how to apply the right test at the right stage. The Scope and Specimens in Forensic Immunology topic covers the specimen types and analytical scope in more detail.